secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001651308-23-000125
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene Q2 product revenue $553.7M (+82% YoY); BRUKINSA sales $308M; settles BMS arbitration
--------------------------------------------------------------------------------

- Settled BMS-Celgene dispute: BMS transfers 23.3M BeiGene shares to BeiGene, no cash payment; arbitration dismissed.
- BRUKINSA global sales $308M (+139% YoY); U.S. sales $223.5M (+153% YoY); tislelizumab China sales $149.5M (+42.5% YoY).
- Net loss improved to $381.1M from $565.7M YoY; operating leverage driven by 82% revenue growth vs 15% expense growth.
- Regained full global rights to TIGIT inhibitor ociperlimab from Novartis; partnered with DualityBio for preclinical ADC.
- Cash, equivalents and short-term investments $3.5B at June 30, down from $4.5B at year-end 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000125/0001651308-23-000125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000125/bgne-20230801.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer